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Introduction
It is considered that sudden death in patients with coronary artery disease is generally due to ventricular tachyarrhythmias ' 1 '. The MILIS and the MPIP studies have shown that the presence of frequent premature ventricular complexes (PVC) in patients surviving an acute myoeardial infarction is an independent marker of a higher risk for sudden death during short-term and medium-term follow-up periods' 2 -3 '. Ruberman et al. have suggested that the time elapsed from the myoeardial infarction when PVC are detected bears no relation to the adverse prognostic meaning of the arrhythmia' 4 '. The role of antiarrhythmic drug treatment in these patients is controversial. Studies so far reported are incon-elusive and the use of antiarrhythmic agents in patients with an old myoeardial infarction and documented frequent and/or complex PVC is not scientifically based' 5 '. Many physicians are not aware of the potential dangers of prescribing antiarrhythmic drugs in patients with PVC and an old myoeardial infarction' 6 '. The arrhythmogenic effect of antiarrhythmic drugs has been documented in this type of patient using Holter and exercise tests as monitoring tools' 7 '. Gomes et al. have shown that programmed ventricular stimulation can induce VT or VF in some patients with frequent PVC' 8 '. Theoretically speaking patients with an old myoeardial infarction and frequent PVC in whom VT is not induced at a basal stimulation study might develop severe ventricular arrhythmias should the stimulation protocol be repeated after the administration of antiarrhythmic drugs. In this report we describe the use of programmed ventricular stimulation to evaluate the arrhyth- Lown   11  II  II  II  11  II  II  II  II  11  IV-A  11  II  III  IV-A  II  IV-A  IV-B  IV-A  II  11  II and stimulation-induced BAS   320  220  230  200  250  240  210  210  230  210  240  200  210  230  220  230  210  240  240  230  250  250   RV ERP   MEX   360  240  210  180  230  240  250  210  220  210  240  210  210  240  230  220  230  230   ---PFN   340  -250  -260  280  --------220  240  240  240  260  250   RVP-QRS   BAS   230  150  150  190  180  220  180  150  150  190  180  170  140  200  200  150  160  160  190  165  190  185   MEX   260  160  160  200  220  230  180  160  150  210  180  180  160  200  200  150  170  180   ---width   PFN   260  -200  -230 mogenic potential of two class I antiarrhythmic drugs which are extensively used in Europe to 'treat' frequent and complex PVC in patients who have had a myocardial infarction.
Materials and methods
The study was performed on 22 patients with a previous myocardial infarction who consecutively accepted to undergo a stimulation study after Lown class II to IV ventricular arrhythmias had been observed during periods of ECG monitoring prior to or during routine exercise tests while not on antiarrhythmic drugs. All but one patient were male and the mean age was 55 ± 10 years. The antecedent myocardial infarction (anterior in 12 and inferior in 10 patients) had occurred 26 ± 34 months prior to the stimulation study. None of the patients was in heart failure nor had any of them had documented VT or a history of syncope or palpitations, except for 2 patients who had an A-V nodal reentry tachycardia. Six patients were on digitalis, beta-blockers or diltiazem, alone or in combination and 16 patients were on no drugs other than nitrates.
Programmed ventricular stimulation was performed in the fasting state 30-45 minutes after the oral administration of 015 mg kg~' of diazepam. Four multi-electrode catheters were percutaneously introduced via one femoral vein and under fluoroscopic guidance were positioned at several intracardiac sites (high right atrium. His bundle region and apex and outflow tract of the right ventricle). Programmed stimulation was performed with pulses 2 ms wide at twice diastolic threshold. S 2 , S2S3 and S2S3S4 extrastimuli were introduced during a regular ventricular paced rhythm (S,Si) utilizing 3 different basic driving rates (100, 120 and 150 ppm), both from the apex and the outflow tract of the right ventricle. End-points of this protocol were the induction of VF or sustained VT requiring DC shock cardioversion or the completion of the protocol. Four intracardiac bipolar leads (high right atrium. His, apex and outflow tract of the right ventricle) and 6 surface electrocardiographic leads (I, II, III, V,, V 6 and aVR) were simultaneously recorded on paper by means of a multichannel Mingograf and stored on magnetic tape for subsequent play-back.
After the basal study. following the administration of mexiletine (loading dose of 3-5 mg kg" 1 over 5 min followed by a constant intravenous infusion at a rate of 0-07 mg kg" 1 min" 1 ). Two patients were restudied after intravenous propafenone (2-5 mg kg" 1 over 10 min) and 8 patients underwent a repeat study on the subsequent day to undergo the same stimulation protocol between 90 and 150 min after the oral administration of 450 mg of propafenone (single dose). In 6 of the latter 8 patients mexiletine had also been tested at the end of the basal study.
Grading of induced ventricular arrhythmias was made according to the following arbitrary definitions. Repetitive ventricular responses (RVR): from one (single RVR) to 5 consecutive ventricular complexes (multiple RVR) elicited after the last delivered stimulus. Nonsustained VT: VT consisting of more than 5 consecutive ventricular complexes and spontaneously terminating in less than 30 seconds. Sustained VT: VT lasting for more than 30 seconds or resulting in rapid hemodynamic deterioration prompting immediate cardioversion. Student's r-test, analysis of variance, chi-square and Fisher's exact tests were utilized when appropriate. Data are expressed as the mean ± one standard deviation.
Results
As shown in Fig. 1 , all 22 patients developed at least single RVR in response to programmed ventricular stimulation during the basal stimulation study. In 11 patients (50%) only RVR were induced, whereas 3 patients (14%) developed nonsustained VT, 7 sustained VT (32%) and the remaining patient VF. Laboratory induced sustained VT was monoform in 6 patients (with 2 distinct uniform VTs in 2 of them) and multiform in the remaining patient. Nonsustained VT was monoform in 2 of the 3 patients in whom this was the most severe elicited arrhythmia and multiform in the third case. Two nonsustained VT were also induced in 2 patients who developed sustained VT on continuing the stimulation protocol. The R-R interval of the uniform VT was 260 ± 60 ms and 218 ± 23 ms for the sustained and nonsustained arrhythmias, respectively (P = 0-22, not significant).
During the control study of the 18 patients receiving iv mexiletine, 3 developed nonsustained VT, 6 sustained VT (with 2 morphologies in 2 patients) and 1 VF. After mexiletine a nonsustained multiform VT was elicited in 3 patients, sustained VT in 8 (monomorphic in 5 and pleomorphic in 3) and VF in 1 case (not significant) (Figs 1 and 2 ). In the 8 patients with sustained VT following mexiletine, 12 distinct VT were elicited. During the control study of the 10 patients of the propafenone group, nonsustained VT was induced in 1, sustained monomorphic VT in 2, sustained multiform VT in 1 and VF in 1. Following propafenone 2 patients developed nonsustained multiform VT and 8 sustained VT (P = 004). Sustained VT after propafenone was monomorphic in 4 patients and uniform pleomorphic in the other 4 (a total of 16 different morphologies were induced in these 8 patients). As shown in Fig. 1, only 4 of the 11 patients with RVR during the control study remained in a similar category after the drugs while the other 7 patients developed more advanced forms of ventricular arrhythmias (sustained VT in 3 and VF in 1, the rest nonsustained VT). Thus, an arrhythmogenic effect of the antiarrhythmic drugs was observed in 64% of these patients (P = 0004). One of the patients with RVR during the control study, spontaneously developed sustained VT after both mexiletine and propafenone. In addition, 6 of the 14 patients with RVR or nonsustained VT during the control study developed sustained VT or VF after drug administration (P = 0016). Conversely, only 1 of the 8 patients with sustained VT or VF during the by guest on March 4, 2016 http://eurheartj.oxfordjournals.org/ Downloaded from basal study developed RVR after drug administration. In the remaining 3 patients with a nonsustained VT at the control study, a sustained VT was induced in 2 and RVR in the third during the postdrug protocol.
The R-R interval of sustained VT induced after both drugs tended to be slower than that of the control sustained VT (293 ± 56 and 332 ± 77 ms, respectively, vs 260 ± 60 ms, P = 0052). The R-R interval of the 16 morphologically distinct sustained VT induced in 8 patients after propafenone was significantly slower than that of the sustained uniform VT elicited during the control study (P = 003) (Fig.  3) . The proportion of patients with stimulation induced sustained ventricular tachyarrhythmias tended to increase after drug administration although the differences are not statistically significant due to the small size of the series. Sustained VT or VF was elicited in 8 patients (36%) during the control study, in 9 of 18 patients (50%) after mexiletine and in 8 of 10 (80%) following propafenone.
II
The average number of extastimuli required to induce sustained VT or VF was similar in the basal state and after mexiletine (2-5 ± 0-5 and 2-3 ± 1, respectively) and tended to be smaller following propafenone (1-6 ± 0-9). Three ventricular extrastimuli were required to initiate sustained VT during the control study in 4 of 8 patients (50%) and after mexiletine in 4 of 9 (44%) in contrast with only 1 of 8 (13%) following propafenone. Although a trend is evident the differences are not statistically significant.
The mean ventricular effective refractory period during the control study in the mexiletine group and after the latter drug were similar (228 ± 27 ms vs 231 ± 36 ms, respectively). In the propafenone group the mean effective refractory period was 246 ± 29 ms before the drug and 258 ± 33 following propafenone. Differences in both cases are not significant.
The QRS width was measured during ventricular pacing as an estimate of intraventricular conduction velocity using the same basic driving rate and stimulation site at the basal state and after drug administration. The surface ECG lead in which this value was largest was selected for measurements, otherwise lead V! was utilized for that purpose. The QRS complex significantly widened following both antiarrhythmic substances (from 175 ± 26 to 186 ± 30 in the mexiletine group and from 183 ± 26 to 214 ± 28 ms in the propafenone patients; P = 0009 and 0-016, respectively).
Discussion
In this study we report our preliminary observations on the arrhythmogenic potential of antiarrhythmic drugs as assessed by programmed ventricular stimulation in patients with an old myocardial infarction in whom class II to IV PVC have been documented. Previous studies have shown that programmed ventricular stimulation can induce nonclinical sus-tained ventricular tachyarrhythmias in many patients with underlying organic heart disease, postinfarction scars in particular' 8 ' 10 '. Gomes et al studied 40 patients with an old myocardial infarction with high grade PVC and no evidence of clinical sustained VT or syncope; in 17 of these patients (43%) VT (sustained or nonsustained) or VF were elicited during the stimulation study' 8 '. In 11 of our 22 patients (50%) VT or VF were induced with programmed ventricular stimulation; in most of these patients (7/22, 32%) the induced arrhythmia was sustained VT. In Gomes' study the group of patients with laboratory-induced VT or VF were treated with antiarrhythmic drugs according to the results of serial electropharmacologic tests. Despite this, cardiac mortality in this group of patients was high (32%) and it was suggested that stimulation studies could identify high and low-risk subsets for sudden death among patients with high grade PVCf 8 '. An alternative intepretation is that antiarrhythmic drugs could have facilitated the development of sustained ventricular tachyarrhythmias. A controlled study in this regard is therefore needed. Veltri et al. studying 19 patients with documented asymptomatic nonsustained VT and underlying coronary artery disease, were able to induce VT in 9 cases (47%) (5 sustained and 4 nonsustained); although this series is too small to draw conclusions, the authors suggested that a low ejection fraction, more than the ability to induce VT, predicted the risk for subsequent cardiac death and/or sustained VT or VF 1 " 1 .
A problem which must be solved is whether these patients should receive antiarrhythmic medication on a chronic basis. The prophylactic use of antiarrhythmic drugs in patients with frequent or complex PVC has not been shown to prevent sudden death' 5 '. Moreover, the use of these agents can facilitate the development of clinical sustained ventricular tachyarrhythmias' 712 '. Neither Gnomes et a/nor Veltryff al, evaluated the arrhythmogenic effect of antiarrhythmic drugs in those patients in whom nonsustained ventricular arrhythmias were induced in the basal state' 811 '. Sixofthe 14 patients in our series with RVR or nonsustained VT during the control study (43%) developed sustained VT or VF after class I antiarrhythmic drugs (P = 0-016). In addition, only 2 of the 8 patients with sustained VT or VF during the basal study developed nonsustained ventricular arrhythmias following drug administration. Our study illustrates that antiarrhythmic drugs can influence the electrophysiologic milieu in patients with potential reentry pathways so that induction of sustained ventricular arrhythmias can be made possible. If in these patients reentry were based on anatomically determined circuits, the administration of antiarrhythmic drugs can be arrhythmogenic. Whereas in the control state some patients may not be able to develop ' sustained VT due to collision of the activating front against the tail of refractoriness within the reentry pathway, the administration of an antiarrhythmic drug can make it possible to perpetuate a circus movement should conduction velocity be reduced more than the refractory periods are prolonged in the components of the circuit' 6 '. In our patients ventricular refractoriness was very modestly modified after drug administration. Although the effect of drugs on the components of the reentry pathway may be different, the use of agents that would lengthen ventricular refractoriness more significantly would be more advantageous from the therapeutic view point. * In this regard propafenone seemed to be more potent than mexiletine (although due to the size of this series differences were not significant); however, propafenone was more 'arrhythmogenic' and in 80% of the tested cases a sustained VT was elicited after drug administration. This finding seemed to be due to the effect of propafenone on conduction velocity. Sustained VT elicited after propafenone were significantly slower than those induced in the control study. Although the trend towards slower conduction velocity after propafenone is obvious, both drugs widen the QRS complex significantly. Our study was not aimed at comparing the arrhythmogenic power of the ' 2 tested drugs so that conclusions regarding which of them is more 'dangerous' cannot be drawn from our " data. A drug such as mexiletine which slows down conduction at the ventricular level but to a lesser degree than propafenone, might in fact be more dangerous. The reduction in conduction velocity can be sufficient to enable the perpetuation of a ventricu-' lar tachyarrhythmia that is fast enough to result in severe hemodynamic deterioration. A drug that further slows conduction velocity could at least prevent very fast ventricular rates if VT supervenes.
Our preliminary observations in this study illustrate that the use of anti-arrhythmic drugs in patients . with an old myocardial infarction and class II to IV PVC, can facilitate the development of major arrhythmic events at least as assessed by programmed electrical stimulation. The meaning of the induced ventricular arrhythmias both in the basal state and after drug administration is unknown so that we do not claim that our methodology should be considered as A number of trends observed in our study are of concern: (1) the proportion of patients developing sustained VT and VF in response to our stimulation protocol increased from 36% in the basal state to 50% after mexiletine and to 80% after propafenone, (2) one patient without clinical evidence of VT, spontaneously developed sustained VT both after mexiletine and propafenone, (3) only 1 of the 8 patients with sustained VT and VF at the basal study remained with RVR after drug administration, (4) only 5 of the 14 patients with nonsustained ventricular responses in the basal study (including nonsustained VT) remained in a similar category after drug administration, (5) the initiation of sustained VT after propafenone tended to be easier than in the control state as judged by the minimal number of ventricular premature stimuli required to elicit the arrhythmia. In respect of positive trends we can mention the tendency towards slower rates of sustained VT induced after both drugs, particularly propafenone. This fact might prevent the death of the patient should VT develop.
This study is to be continued with follow-up data and a larger series of patients to determine if stimulation-induced sustained VT in patients with an old myocardial infarction and frequent PVC are markers of a higher risk of clinical events. The major conclusion of this preliminary report is to express our concern about the practice of treating asymptomatic PVC in patients with a postmyocardial infarction scar before the beneficial effect of antiarrhythmic drugs is proved.
